Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

Marquette, Charles‐Hugo; Boutros, Jacques; Benzaquen, Jonathan; Ferreira, M.; Pastré, Jean; Pison, Christophe; Padovani, B.; Bettayeb, Faiza; Fallet, Vincent; Guibert, Nicolas; Basille, Damien; Ilié, Marius; Hofman, Véronique; Hofman, Paul; Israël‐Biet, Dominique; Chabot, F.; Guillaumot, Anne; Deslée, G.; Perotin, Jeanne-Marie; Dury, Sandra; Mal, Hervé; Marceau, Armelle; Kessler, Romain; Vergnon, Jean‐Michel; Pélissier, Carole; Palma, Fabrice Di; Cuvelier, A.; Patout, Maxime; Bourdin, Arnaud; Gamez, Anne Sophie; Andréjak, Claire; Poulet, Claire; François, G; Jounieaux, Vincent; Roche, Nicolás; Jouneau, S.; Brinchault, Graziella; Bonniaud, Philippe; Zouak, Ayoub; Scherpereel, Arnaud; Baldacci, S.; Cortot, A.; Mornex, J. F.; Steenhouwer, François; Leroy, Sylvie; Berthet, Jean‐Philippe; Fontas, Éric; Bulsei, Julie; Cruzel, Coralie; Pradelli, Johanna; Fontaine, Maureen; Maniel, Charlotte; Griffonnet, Jennifer; Butori, Catherine; Selva, Éric; Poudenx, M.; Aguilaniu, B.; Ferretti, G.; Arbib, François; Briault, Amandine; Toffart, Anne‐Claire; Dahalani, Raissa; Destors, Marie; Chanez, Pascal; Greillier, L.; Astoul, Philippe; Barlési, Fabrice; Gaubert, Jean-Yves; Mazières, Julien; Marchand-Adam, S.; Cadranel, Jacques; Chaabane, Nouha; Izadifar, A.; Rosencher, L.; Ruppert, Anne-Marie; Vieira, T.; Mathiot, N.

doi:10.1016/s2213-2600(20)30081-3

Cited by 105 publications

(73 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are several reports on using various biomarkers, including metabolites [20,21], volatile compounds [22], cDNA [23], miRNA [24], circulating tumor cells [25], antigens, and autoantibodies [26] to detect lung cancer. It is expected that these methods should reduce the false-positive rate when used in combination with LDCT.…”

Section: Introductionmentioning

confidence: 99%

9G TestTM Cancer/Lung: A Desirable Companion to LDCT for Lung Cancer Screening

Choe

Chae

Lee

et al. 2020

Cancers

View full text Add to dashboard Cite

A complimentary biomarker test that can be used in combination with LDCT for lung cancer screening is highly desirable to improve the diagnostic capacity of LDCT and reduce the false-positive rates. Most importantly, the stage I lung cancer detection rate can be dramatically increased by the simultaneous use of a biomarker test with LDCT. The present study was conducted to evaluate 9G testTM Cancer/Lung’s sensitivity and specificity in detecting Stage 0~IV lung cancer. The obtained results indicate that the 9G testTM Cancer/Lung can detect lung cancer with overall sensitivity and specificity of 75.0% (69.1~80.3) and 97.3% (95.0~98.8), respectively. The detection of stage I, stage II, stage III, and stage IV cancers with sensitivities of 77.5%, 78.1%, 67.4%, and 33.3%, respectively, at the specificity of 97.3% have never been reported before. The receiver operating characteristic curve analysis allowed us to determine the population-weighted AUC of 0.93 (95% CI, 0.91–0.95). These results indicate that the 9G testTM Cancer/Lung can be used in conjunction with LDCT to screen lung cancer. Furthermore, obtained results indicate that the use of 9G testTM Cancer/Lung with LDCT for lung cancer screening can increase stage I cancer detection, which is crucial to improve the currently low 5-year survival rates.

show abstract

Section: Introductionmentioning

confidence: 99%

9G TestTM Cancer/Lung: A Desirable Companion to LDCT for Lung Cancer Screening

Choe

Chae

Lee

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…CellSearch) and cell size-exclusion filtration to enrich large cell size CTCs (>WBC size) are the most representative conventional approaches. However, it has been realized that clinically relevant small cell size CTCs (≤WBC size), such as mesenchymal CTCs [75], are lost throughout the filtered depletion of WBCs, raising non-negligible concerns with respect to specificity and sensitivity for cell filtration strategy [76,77], particularly for lung cancer CTC detection [78]. CellSearch technology relies on positive expression of EpCAM and cytokeratin (CK) for isolation and identification, respectively.…”

Section: Conventional Strategies To Detect Lung Cancer Ctcsmentioning

confidence: 99%

Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer

Lin¹

2021

Lung Cancer - Modern Multidisciplinary Management

View full text Add to dashboard Cite

Risk stratification, prognostication and longitudinal monitoring of therapeutic efficacy in lung cancer patients remains highly challenging. It is imperative to establish robust surrogate biomarkers for identifying eligible patients, predicting and effectively monitoring clinical response as well as timely detecting emerging resistance to therapeutic regimens. Circulating tumor biomarkers, analyzed by liquid biopsy, are primarily composed of nucleic acid-based circulating tumor DNA (ctDNA) and an aneuploid cell-based category of circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs). Unlike ctDNA, cancer cells are the origin of all categories of various tumor biomarkers. Involvement of aneuploid CTCs and CTECs in tumorigenesis, neoangiogenesis, tumor progression, cancer metastasis and post-therapeutic recurrence has been substantially investigated. Both CTCs and CTECs possessing an active interplay and crosstalk constitute a unique category of cellular circulating tumor biomarkers. These cells concurrently harbor the intact cancer-related genetic signatures and full tumor marker expression profiles in sync with disease progression and therapeutic process. Recent progress in clinical implementation of non-invasive liquid biopsy has made it feasible to frequently carry out ctDNA analysis and unbiased detection of a full spectrum of non-hematologic circulating rare cells including CTCs and CTECs in lung cancer patients, regardless of variation in heterogeneous cell size and cancer cell surface anchor protein expression. In situ phenotypic and karyotypic comprehensive characterization of aneuploid CTCs and CTECs, in combination with single cell-based genotyping and improved ctDNA analyses, will facilitate and benefit multidisciplinary management of lung cancer.

show abstract

“…Promising results were obtained; 5 of the 168 patients developed a lung cancer several months after the detection of CTCs, whereas no patients without CTCs developed lung cancer, which underlined the strong specificity and sensitivity of the test 17 . However, a recent study (AIR study project) performed by the same group of investigators and aimed at validating the first study with an independent cohort of patients did not confirm the initial results 18,19 . This prospective, multicentric study was undertaken in France with an enlarged cohort of 614 patients from 21 hospitals 19 .…”

Section: Introductionmentioning

confidence: 98%

“…Finally, the validation study was prospective and involved a large number of staff members, in particular technicians who filtered the blood on machines located at different hospitals in France (Nice, Paris, Toulouse, or Nancy). However, the blood from patients residing in other cities who were participating in the study was transported to the Nice Hospital 19 . Several differences in the preanalytical procedures of the different hospitals, in particular concerning the filtration of the blood and/or the type of blood collection tubes used (ethylenediaminetetraacetic acid [EDTA] or Streck BCT [Streck, Omaha, Nebraska] tubes), was noted 19 .…”

Section: Introductionmentioning

confidence: 99%

“…However, the blood from patients residing in other cities who were participating in the study was transported to the Nice Hospital 19 . Several differences in the preanalytical procedures of the different hospitals, in particular concerning the filtration of the blood and/or the type of blood collection tubes used (ethylenediaminetetraacetic acid [EDTA] or Streck BCT [Streck, Omaha, Nebraska] tubes), was noted 19 . In addition, follow‐up of the patients using chest imagery after blood collection was limited to 2 years in the validation study whereas the mean follow‐up was 3.2 years in the initial study 17,19 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers

Hofman

2020

Cancer Cytopathology

Self Cite

View full text Add to dashboard Cite

Screening for lung cancer has become a reality in certain countries, most notably the United States, but its implementation currently is under discussion and not established in many nations, including France. Screening for lung cancer currently is proposed using a low‐dose computed tomography scanner. However, this approach lacks sensitivity and specificity, and could be improved when combined with a blood test (so‐called “liquid biopsy”). Such tests attempt to detect biomarker (s) of early cancer development. Thus, numerous studies performed within the last few years have examined different blood components including circulating tumor cells and free DNA and other circulating elements such as microRNAs, exosomes, antibodies, and proteins. Recent studies have highlighted the value of seeking a signature for the methylation of circulating free DNA, which can be specific for certain solid tumors, including lung carcinoma. The current study describes some recent developments in the use of liquid biopsies for the detection of early‐stage lung cancers, even those that are not yet visible using a low‐dose computed tomography scanner.

show abstract

Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

Cited by 105 publications

References 42 publications

9G TestTM Cancer/Lung: A Desirable Companion to LDCT for Lung Cancer Screening

9G TestTM Cancer/Lung: A Desirable Companion to LDCT for Lung Cancer Screening

Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer

Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers

Contact Info

Product

Resources

About